Slide 1: NeurAxis, Inc.
NeurAxis, Inc. Reimagining an Evidence-Based, Drug Free Alternative For Children September 21, 2023 NeurAxis is committed to providing solutions that create value and provide better patient outcomes. We believe in improving lives and minimizing suffering, Through innovation and research, we are reim
Slide 2: Forward Looking Statements
Forward Looking Statements Information included herein has been prepared by NeurAxs, In. (’NeurAsis’) or obtained from sources believed to be reliable, but the accuracy or completeness of such information is not guaranteed by and should nat be construed as a representation by NeurAxis or any other p
Slide 3: NeurAxis PENFS: First FDA Indicated Treatment for Pediatric FAP/IBS
NeurAxis PENFS!: First FDA Indicated Treatment for Pediatric FAP/IBS2 Strong Data = Strong Policy Coverage & Reimbursement = Strong Revenue Growth Large Global Market with Significant Unmet Need Unique, Innovative Product ‘Supported by Clinical Evidence + $30B+ TAM? for target pipeline indications 2
Slide 4: $30B+ Total Addressable U.S. Market for Pipeline Indications
$30B+ Total Addressable U.S. Market for Pipeline Indications Near-to-mid term Target Mid-term Target $8 any $38 s2e vomiting Concussion $9B sv 38 Pediatric FaPIBS Vornting TAM’ $18 FAPIBS $28 Functional Dyspepsia (Nausea) Entering Pediatric markets first with: * First FDA cleared treatment for Pedia
Slide 5: DGBIs: A Problem with an Unmet Need
DGBIs: A Problem with an Unmet Need + No approved therapies for children with abdominal pain related disorders of the gut-brain interactions (DGBIs) * Disorders negatively impacts quality of life and ability to function (attend school, sports, and social activities) + Insufficient data to support th
Slide 6: Abnormal processing of signals to and from the gut
Abnormal processing of signals to and from the gut 2) fi Gut Brain Axis isorders of the Gut-Brain Interaction (DGBIs) Irritable Cyclic Bowel Vomiting Syndrome Syndrome Functional Dyspepsia Gastroenterolo; ey Eunctional Dyspepsia — pain or discomfort located in the upper abdomen Inritable Bowel Syndr
Slide 7: Data Does Not Support Standard Pharmacotherapy in Children with IBS
Data Does Not Support Standard Pharmacotherapy in Children with IBS No data to support use of Antidepressants in Children with Functional Abdominal Pain: + Amitriptyline (TCA) did not beat placebo in RCT! * Citalopram (SSRI) did not beat placebo in RCT? Significant Risk of TCA Side Effects in Childr
Slide 8: Percutaneous Electrical Nerve Field Stimulation (PENFS)
Percutaneous Electrical Nerve Field Stimulation (PENFS) “Facil (V1) “Glossopnaryageal | 1.Access *———* 2.Stimulate ©*———- 3. Change Direct access to central Stimulation reduces firing Induces changes in brain nervous system (CNS) of amygdala pathways/connectivity through peripheral cranial nerves —~
Slide 9: Established Technology with Demonstrated Safety and Efficacy
Established Technology with Demonstrated Safety and Efficacy What is IB-Stim™ * PENFS system intended for patients 11-18 years of age with functional abdominal pain (FAP) associated with IBS * Aids in pain reduction via neuromodulation to branches of Cranial Nerves (V,VII,IX and X) * Non-drug and no
Slide 10: IB-Stim Advantages Over Traditional Care
IB-Stim™ Advanta Over Traditional Care STM Traditional care FDA Indicated No FDA Approved Treatments Rx often Peretancovs Elect! Neve Fed Stimulation friable Bowel Containing FDA Syndrome Black Box Labels : Suicidal Ideation, Eraiecm) Depression, & Weight Gain Targets The Brai Localized Gut Ax and P
Slide 11: Patient Journey
Patient Journey Gesmma Qe pz SY, AS 1, Persistent Pain Patient experiences frequent and often debilitating abdominal pain (weeks, months or years) & 5, Follow-Up + Patient takes off at home after 5 days, gets a 2-day break, then visits a physician for next prescribed treatments for up to 4 weeks. +
Slide 12: IB-Stim Research — By the Numbers
ae LLLLLC“(t‘SCSCSC‘(§$TNNC.-U@Bs] IB-Stim™ Research — By the Numbers 4 Strong Data = Strong Policy Coverage & Reimbursement = Strong Revenue Growth FI 1 Current =P Publications x Double Blind Registry a Placebo Controlled Data suey sy Clinical fMRI Quality of Real World : Study Life Data Clinical D
Slide 13: NeurAxis PENFS Technology: Peer-Reviewed Publications
NeurAxis PENFS Technology: 14 Peer-Reviewed Publ Percutaneous Electrical Nerve Field Stimulation Compared to} indard Medical Therapy in Adolescents with Fung PERCUTANEOUS ELECTRICAL NERVE FIELD STIMULATION MODULATES CENTRAL PAIN PATHWAYS AND ATTENUATES. POST-INFLAMMATORY VISCERAL AND SOMATIC HYPERAL
Slide 14: Growing Body of Clinical Evidence
Growing Body of Clinical Evidence THE LANCET Nov Improvement of Global Symptoms in Patients Gastroenterology & Hepatology 2017 with Irritable Bowel Syndrome Global Symptom Improvement 100 ad 82 80 6 67 © a 48 PENIS os * # sham ao, cad 22 22 2 10 ot 22 23 24 *Percent of patients reporting improvement
Slide 15: FDA Benchmark for Clinically Meaningful Endpoint
FDA Benchmark for Clinically Meaningful Endpoint 230% Improvement in Pain 10" 2 1B-Stim Treatment for abdominal pain-related functional = Sham - 9 9 3 gastrointestinal disorders in adolescents: cor $ so" Number Needed to Treat (NNT): Zao The number of patients that need to be treated for one patient
Slide 16: Functional Disability Scores at Long-Term Follow-Up
Functional Disability Scores at Long-Term Follow-Up Improvement in Functional Disability in Patients with Irritable Bowel Syndrome *» Moderate disability Minimal disability 5 _ Improving functional disability 3 * (attending school and activities) is a 0 marker of overall health and clinically 8 mean
Slide 17: IB-Stim Long Term Data: Cincinnati Children's Hospital
IB-Stim™ Long Term Data: Cincinnati Children’s Hospital Effect of percutaneous electrical nerve field stimulation on Abdominal Pain Index mechanosensitivity, sleep, and psychological comort adolescents with functional abdominal pain disorders <0,0001 Neha R Santucci*® | Christopher King? | Khalil l.
Slide 18: PENFS compared to standard medical therapy in adolescents
Percutaneous electrical nerve field stimulation compared to standard medical therapy in adolescents with functional abdominal pain disorders [Neha R. Santucci, Rash Sahay’, Khali. E-Chamnnas Kahleb Graham, Mikaela Wheattey", Madeleine Vandenbin Jennifer Hardy’ and Lin Fei IB-Stim was equivalent or b
Slide 19: IB-Stim vs. Drugs Competitive Landscape
IB-Stim™ vs. Drugs Competitive Landscape Antidepressants Adult Use (Peripherally Acting at the Gut Level) IB-Stim™ Amitriptyline Citalopram Amitiza Linzess Trulance Viberzi FDA Approved for IBS in Children and Adolescents Improves Functional Disability Targets Brain-Gut Axis Better Than Placebo for
Slide 20: Clinical Study Timeline 2023E-2027E
2023E 2024E 2025E 2026E 2027E Clinical Study* itable Irritable Children's Wisconsin RCT** Prospective | Children's Hospital of Orange County RCT** Mw Children's Wisconsin Single Blind |! | => Clinical Study JN FDA Submission FDA Indication Launch / Commercialization nosh whet titi NeurAxis) 20
Slide 21: IB-Stim Reimbursement
IB-Stim Reimbursement Market Access Plan Established Successful Proof (eerie SoM Ry SHARE, Concept Coverage Pol * Versus Placebo (Completed) + NASPGHAN Written Support + BCBS Massachusetts + CAT III (Effective July 2022) + Long-term Study (Completed) + AAP Written Support + BSBS Nebraska + CAT Appli
Slide 22: Go-to-Market Strategy
Go-to-Market Strategy Strong Data = Strong Policy Coverage & Reimbursement = Strong Revenue Growth 2023 Policy Coverage Commercialization Strategy Reimbursement Strategy 4 plans 475M CPT code* * CAT II code (0720T) Insurance plans ‘of Comm Lives in A Lives covered ° State a Us Price sass BCBS of MA
Slide 23: NeurAxis IP Portfolio issued and pending patents
NeurAxis IP Portfolio 8 issued and 18 pending patents = Device = Method U.S. IP runs through 2039 for now ° International IP in process Freedom to operate completed aNeurAxisY 23
Slide 24: In-House Capabilities, Manufacturing Capacity, Quality Management System
In-House Capabilities Manufacturing Capacity Quality Management System + Office and factory in Indiana + Controlled, repeatable, monitored + ISO 13485:2016 Certified * 69,000 square foot facility production process * FDA registered * Offices, factory, environmentally * Kit production capacity suffic
Slide 25: Medical Advisory Board
Medical Advisory Board Y1@ @@ Dr. Samuel Nurko Dr. Carlo Di Lorenzo Dr. Rachel Rosen Dr. Kahlil El-Chammas Dr. Miranda van Tilburg Dr. Leonel Rodriguez O sis: . Children: N 6 ildren's NATIONWIDE ildren's Hospital CHILDREN'S Hospital a . ‘Yale University Until every chilis welt endings Uri every chil
Slide 26: Board of Directors
Board of Directors Beth Keyser Mitch Watkins Timothy Henrichs Brian Carrico Dr. Chris Brown Board Member Board Member Board Member Chief Executive Officer, Director Of Innovation, Board Member Founder, Board Member Collective Experience mcinthen a —FeRuMO = Resxove @ = featiigien Follett [BAM
Slide 27: Management Team
Management Team Brian Carrico Dr. Adrian Miranda Chief Executive Officer, Chief Medical Officer Board Member St.JUDE Mpicar BA MEDICAL, [BARID cours OF WISCONSIN Children’s Hospital of Wistsin © oer John Seale Chief Financial Officer AICPA) ‘American Insitute of CPAS" A Dan Clarence Dr. Tom Carrico
Slide 28: NeurAxis Milestones
NeurAxis Milestones 2022 20248 “CAT III CPT Code Effective - july 1, 2022 +225M+ Covered Lives *6 Publications + Functional Dyspepsia (Nausea); +135 Published Patients (=) 1Q 2024 *Cyclic Vomiting Syndrome; “BCBS MA Policy Coverage Mid-2026 +4.75M Covered Lives *Post-concussion Syndrome; Q1 2026 *CI
Slide 29: Capital Structure & Financial Snapshot
Capital Structure & Financial Snapshot Offering 17.34% Other AT92% 1. Gres sg dudes resarehdeves na or dewslpmentiepanson Financial Snapshot Revenue * ~$1.45 million YTD June 2023 * ~$2.7 million in 2022 Gross Margin * 88.7% YTD June 2023 * 88.9% in 2022 WNeurAxis y 29
Slide 30: Key Investment Highlights
Key Investment Highlights Strong Data = Strong Policy Coverage & Reimbursement = Strong Revenue Growth Large Global Market with Significant Unmet Need * $30B+ TAM? for target pipeline indications + $98+ TAM for target pediatric indications (near-to-mid term) + $218 TAM? for target adult indications